cart (0)
Recently added item(s)

View Cart

  • thumbnail Apple Pharmaceuticals thumbnail

Hepcvir - 12 weeks

HepatitisC-Cipla-Sofosbuvir-400mg-Hepcvir

Availability: In stock

Special Price $ 450

Hepcvir - 12 weeks DESCRIPTION

Hepcvir (Sofosbuvir ) Brand name: Hepcvir Active Ingeridents(Generic Name) : Sofosbuvir Company Name: Cipla Package: 15 Tablets/Bottle Strength : 400mg Indication: It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sofosbuvir allows most patients to be treated successfully without... Read Below

Hepcvir (Sofosbuvir )
Brand name: Hepcvir
Active Ingeridents(Generic Name) : Sofosbuvir
Company Name: Cipla
Package: 15 Tablets/Bottle
Strength : 400mg
Indication:
It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sofosbuvir allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV.

Sofosbuvir is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Sofosbuvir also used along with the daclatasvir for the genotype 3 indication and also available pangenotypic combination of sofosbuvir and velpatasvir. Sofosbuvir is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of sofosbuvir plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Mechanism of action:
Sofosbuvir contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.
Dosage and Administration:
The recommended daily dose of Sofosbuvir is 400mg tablet to be taken once daily with or without food. Sofosbuvir should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Side effects:
Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following

o Fatigue , headache
Adverse events associated with the use of Sofosbuvir in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

o fatigue,headache, nausea, insomnia, anemia

Precaution: Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

Store: Store at 25°C in a dry place.